Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL4581899 | 0.88 | CTSK (0.47) | CTSKCYP2D6EPHX1CA12CA1 | |
| Acetic Acid SCHEMBL3808908 | 0.84 | CTSK (0.45) | CTSKCYP2D6EPHX1CA12CA1 | |
| Acetic Acid SCHEMBL4581574 | 0.83 | CYP2D6 (0.40) | CTSKCYP2D6EPHX1CA12CA1 | |
| Acetic Acid SCHEMBL3402100 | 0.82 | CTSK (0.44) | CTSKCYP2D6EPHX1CA12CA1 | |
| SCHEMBL18090432 | 0.82 | CTSK (0.51) | CTSKCYP2D6EPHX1CA12CA1 | |
| Acetic Acid SCHEMBL3400867 | 0.81 | CTSK (0.43) | CTSKCYP2D6EPHX1CA12CA1 | |
| Acetic Acid SCHEMBL614057 | 0.81 | CTSK (0.43) | CTSKCYP2D6EPHX1CA12CA1 | |
| Acetic Acid SCHEMBL4757215 | 0.81 | CTSK (0.43) | CTSKCYP2D6EPHX1CA12CA1 | |
| Bicarbonate SCHEMBL3258777 | 0.81 | CTSK (0.45) | CTSKCYP2D6EPHX1CA12CA1 | |
| Acetic Acid SCHEMBL6880640 | 0.80 | CTSK (0.42) | CTSKCYP2D6EPHX1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010075520-A1 | PREPARATION OF GABAPENTIN ENACARBIL INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-07-01 | — | — | WO | disclosed |
| EP-2101752-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | Xenoport, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-2086530-A1 | USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS | Xenoport, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| US-7423169-B2 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2008073257-A1 | USE OF PRODRUGS OF GABA ANALOGS FOR TREATING DISEASES | XENOPORT, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008060572-A1 | USE OF GABAPENTIN AND PREGABALIN PRODRUGS FOR TREATING TINNITUS | XENOPORT, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080058546-A1 | Methods for Synthesis of Acyloxyalkyl Derivatives of GABA Analogs | XENOPORT, INC | 2008-03-06 | — | — | US | disclosed |
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | XENOPORT, INC. | 2006-12-21 | — | — | US | disclosed |
| CN-1675165-A | Method for synthesizing acyloxyalkyl derivatives of GABA analogs | XENOPORT INC (US) | 2005-09-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287250-A1 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | GABRB1, GABRB3, GABBR1 | OPRK1 449/4885CTSK 1672/4885CYP2D6 1278/4885 |
| US-20080058546-A1 | Methods for Synthesis of Acyloxyalkyl Derivatives of GABA Analogs | GABRB1, GABRB3, GABBR1 | OPRK1 449/4885CTSK 1672/4885CYP2D6 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.